Overview

A Pilot Study Assessing EmSam in Bipolar Depression

Status:
Terminated
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This pilot study will evaluate the efficacy of the monoamine oxidase inhibitor (MAOI)EmSam, a selegiline transdermal system (STS), in bipolar depression.
Phase:
Phase 4
Details
Lead Sponsor:
New York State Psychiatric Institute
Treatments:
Selegiline